DNM1L and COVID-19: In hypoxemia caused by COVID-19, SARS-CoV-2 activates Drp1 via phosphorylation at Ser616 through the RIP1/RIP3 [47], resulting in alveolar injury and pulmonary vasoconstriction dysfunction [48].